



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2500

APR 29 2002

RECEIVED

In re the application of: Jochen G. Salfeld, *et al.*

Group Art Unit: 1646

Serial No.: 09/534,717

Examiner: Prasad, S.

Filed: March 24, 2000

For: *Human Antibodies that Bind Human IL-12 and Methods for Producing*

Attorney Docket No.: BBI-093CP

COPY OF PAPERS
ORIGINALLY FILED

Commissioner for Patents
Washington, D.C. 20231

#13
M.G.J
6/26/02


Certificate of First Class Mailing (37 CFR §1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on the date set forth below.

April 17, 2002

Date of Signature and of Mail Deposit

By:


Elizabeth A. Hanley, Esquire
Reg. No. 33,505
Attorney for Applicants

RESPONSE TO RESTRICTION REQUIREMENT

Dear Sir:

This is a response to the Office Action mailed from the Patent Office on November 19, 2001 (Paper No. 10). A separate petition for four-month extension of time is being filed concurrently herewith.

Supplemental Response to Restriction Requirement under 35 U.S.C. § 121

The Examiner has stated that the Applicants' reply filed on August 29, 2001 was not fully responsive to the previous Office Action (dated June 27, 2001). The Examiner has required that Applicants elect a single disclosed species of SEQ ID No. for each of the CDR1, CDR2, and CDR3 regions, as well as the corresponding single sequence for the entire heavy and light chain for prosecution on the merits.

Applicants hereby elect the following:

SEQ ID NO: 25 for the heavy chain CDR3

SEQ ID NO: 26 for the light chain CDR3

SEQ ID NO: 27 for the heavy chain CDR2

SEQ ID NO: 28 for the light chain CDR2

SEQ ID NO: 29 for the heavy chain CDR1

SEQ ID NO: 30 for the light chain CDR1

SEQ ID NO: 31 for the heavy variable chain

SEQ ID NO: 32 for the light chain variable chain

The Examiner has also requested that Applicants elect a single species of therapeutic agent. With respect to the election of a species of a therapeutic agent, Applicants hereby elect the species of "antibodies or agonists of TNF."

With respect to the elected species, it is Applicants understanding that this election is for searching purposes only and upon allowance of the elected claims, the generic claims also will be searched and Applicants will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 C.F.R. § 1.141.

- 3 -

If a telephone conversation with Applicants' attorney would help expedite the prosecution of the above-identified application, the Examiner is urged to call Applicants' attorney at (617) 227-7400.

Respectfully submitted,



Elizabeth A. Hanley, Esq.
Registration No. 33,505
Attorney for Applicants

LAHIVE & COCKFIELD, LLP
28 State Street
Boston, MA 02109
Tel. (617) 227-7400
Dated: April 17, 2002